explore -WSS

explore

author：hotspot 2025-09-27 09:47:25 - browse：12699

Chris O'Meara/AP

Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Let's speed up science by embracing open access publishing

entertainment

WSS

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

ASCO: AstraZeneca says CAR

At ASCO, AstraZeneca reports strong data for breast cancer drug

ASCO: Palliative care found as helpful given virtually as in person

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

STAT wants to know your pick for a great summer read or listen

focus

explore

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Tori Bowie and the unacceptable rates of Black maternal death

Senators tussle over abortion against the backdrop of a presidential campaign

In Memoriam: Notable people who died in 2023

The most pressing bird flu mysteries scientists want answered

Duchenne breakthrough therapy leaves behind pioneering families

BD to buy Edwards patient monitoring unit for $4.2 billion

Hepatitis C has a cure — but many Americans still lack access to it

BMI, flaws aside, is found to be useful estimate of body fat in youth

Wikipedia

BMI, flaws aside, is found to be useful estimate of body fat in youth

NIH documents show early flaws of $1.6 billion long Covid program

Ionis drug prevents swelling attacks due to hereditary angioedema

FDA's Pazdur wants cancer trials to range beyond China alone

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Woman returns to dialysis after doctors remove transplanted pig kidney

hotspot

entertainment

focus

entertainment